Variant · Snv
MTOR E1799K
CI-VAR-00000676Explore in graph →NP_004949.1:p.Glu1799LysNM_004958.3:c.5395G>AClinVar 217823 CIViC 544 rs863225264
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24631838
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Neoplasm1 | ||||||||
| MTOR E1799K | Sirolimus | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1321Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 … (full text at CIViC) PMID 24631838 · Grabiner et al., 2014 · Open in CIViC | civic |
| Focal Cortical Dysplasia1unmapped disease | ||||||||
| MTOR E1799K | Everolimus | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9489The L2427P (c.7280T>C) variant of mTOR was found in brain tissue samples from 2 focal cortical dysplasia type II (FCDII) patients at allelic frequencies of 9.6–12.6% and 6.9–7.3% in biological replica… (full text at CIViC) | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available